主要文件

查看所有文档

PZ0014

利奈唑胺

Name: 利奈唑胺
Brand: SIGMA

≥98% (HPLC), powder, bacterial mRNA translation inhibitor

别名:

N-[[（5S）-3-[3-氟-4-（4-吗啉基）苯基] -2-氧代-5-恶唑烷基]甲基]乙酰胺, PNU-100766, U-100766

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₆H₂₀FN₃O₄

化学文摘社编号:

165800-03-3

分子量:

337.35

UNSPSC Code:

12352200

PubChem Substance ID:

329823683

NACRES:

NA.77

MDL number:

MFCD00937825

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

利奈唑胺, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: >20 mg/mL

storage temp.

room temp

SMILES string

CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCOCC3)c(F)c2

InChI

1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1

InChI key

TYZROVQLWOKYKF-ZDUSSCGKSA-N

说明

General description

利奈唑胺对多种革兰氏阳性菌具有抗菌活性，包括耐青霉素菌、耐甲氧西林菌和耐万古霉素菌。利奈唑胺可通过抑制起始复合物形成降低翻译反应速率，从而缩短新合成肽链长度。此外，它还有减少毒力因子的作用，可减少革兰氏阳性菌产生的毒素。

Application

利奈唑胺已用于棋盘式药物组合 MIC（最小抑制浓度）检测，以确定 ivacaftor是否与利奈唑胺的具有正相互作用。已用于测定最低生物膜抑制浓度和用于治疗脓肿分枝杆菌感染的黑腹果蝇w1118。利奈唑胺已作为抗生素，研究它对大鼠肺部疟疾相关呼吸窘迫综合征(MAARDS)发生发展的影响。作为抗生素与黄苓素联用，研究它对耐甲氧西林金黄色葡萄球菌株的影响。作为抗生素，研究它对浮游生物生长和粪肠球菌生物膜形成的影响。

Biochem/physiol Actions

利奈唑胺是一种恶唑烷类抗菌药。它抑制细菌 mRNA的翻译和是一种弱的、可逆的、非选择性的单胺氧化酶抑制剂。

利奈唑胺是一种恶唑烷酮类抗菌药。它与50S 亚基的细菌 23S 核糖体 RNA 上的位点结合，并阻止功能性 70S 起始复合物的形成，从而抑制细菌 mRNA 翻译。利奈唑胺也是一种弱的、可逆的非选择性单胺氧化酶抑制剂。

Still not finding the right product?

Explore all of our products under 利奈唑胺

pictograms

GHS08

signalword

Danger

hcodes

H372

pcodes

P260 - P264 - P270 - P314 - P501

Hazard Classifications

STOT RE 1 Oral

target_organs

Bone

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Giovanni Sotgiu et al.

The European respiratory journal, 40(6), 1430-1442 (2012-04-13)

Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety and tolerability of linezolid-containing regimes based on individual data analysis. 12 studies (11 countries from three

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Gregory J Moran et al.

The Lancet. Infectious diseases, 14(8), 696-705 (2014-06-10)

New antibiotics are needed to treat infections caused by drug-resistant bacteria. Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity against Gram-positive pathogens. We aimed to assess the efficacy and safety of intravenous to oral tedizolid for

The emerging problem of linezolid-resistant Staphylococcus.

Bing Gu et al.

The Journal of antimicrobial chemotherapy, 68(1), 4-11 (2012-09-06)

The oxazolidinone antibiotic linezolid has demonstrated potent antimicrobial activity against Gram-positive bacterial pathogens, including methicillin-resistant staphylococci. This article systematically reviews the published literature for reports of linezolid-resistant Staphylococcus (LRS) infections to identify epidemiological, microbiological and clinical features for these infections.

查看所有相关文献

全球贸易项目编号

货号	GTIN
PZ0014-25MG	04061835304837
PZ0014-5MG	04061836687359